Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

3D Deep Learning for Brain Tumor Segmentation and Survival Prediction: A Comprehensive Multi-Modal Analysis Using the BraTS2020 Dataset.

Journal of imaging·2026

Same author

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026

Same author

Value operating system: a practical framework to measure outcomes-per-cost at the episode level.

BMJ open quality·2026

Same author

Twelve-Month Metastatic State as a Landmark-Based Prognostic Stratifier in Metastatic Sarcoma.

Cancers·2026

Same author

Locked-Window EQ-5D-5L (Index and VAS) Benchmarking in Sarcoma Care: Rule-Based Traffic-Light Classification Across Two Institutions.

Diseases (Basel, Switzerland)·2026

Same author

Preventing unplanned "whoops" sarcoma surgery: from technical pearls to early referral and network-level quality metrics.

Chinese clinical oncology·2026

Search research articles

Related Experiment Video

Updated: Jun 19, 2025

Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions

Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions

Published on: April 5, 2024

Real-World-Time Data and RCT Synergy: Advancing Personalized Medicine and Sarcoma Care through Digital Innovation.

Philip Heesen^1,2,3, Georg Schelling², Mirko Birbaumer⁴

¹Faculty of Health Sciences & Medicine, University of Lucerne, Frohburgstrasse 3, 6002 Luzern, Switzerland.

|July 27, 2024

Summary

This summary is machine-generated.

This study explores how real-world/time data/evidence (RWTD/E) and randomized controlled trials (RCTs) can improve sarcoma care. Combining these methods enhances personalized medicine and healthcare efficiency.

Keywords:

digital twin healthcare research patient outcome optimization personalized medicine population health management randomized controlled trials (RCTs)real-world/time data/evidence (RWTD/E)sarcoma care target trial emulation value-based healthcare (VBHC)

More Related Videos

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication

Published on: December 15, 2023

Related Experiment Videos

Last Updated: Jun 19, 2025

Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions

Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions

Published on: April 5, 2024

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication

Published on: December 15, 2023

Area of Science:

Healthcare Research
Data Science
Oncology

Background:

Real-world/time data/evidence (RWTD/E) offers granular patient insights for healthcare research.
Randomized controlled trials (RCTs) provide structured data for clinical validation.
Integrating RWTD/E and RCTs can significantly enhance healthcare insights.

Purpose of the Study:

To examine the synergistic potential of prospective RWTD/E and RCTs in healthcare research.
To highlight the impact of combining RWTD/E and RCTs, particularly in sarcoma care.
To advocate for the strategic integration of prospective RWTD/E into healthcare frameworks.

Main Methods:

Exploring the capabilities of RWTD/E in providing real-world, granular patient data.
Analyzing the complementarity between RWTD/E's scope and RCTs' structured environment.
Outlining methodological innovations like target trial emulation for RWTD/E.

Main Results:

The combination of RWTD/E and RCTs offers an enriched perspective on healthcare outcomes and delivery.
Synergistic use fosters advancements in personalized medicine and population health management.
Methodological innovations enhance the precision and applicability of RWTD/E.

Conclusions:

Strategic incorporation of prospective RWTD/E with RCTs can transform sarcoma care.
This integration aims to create an evidence-driven ecosystem for improved patient outcomes.
Enhanced healthcare efficiency and personalized treatment strategies are key benefits.